Practical Geriatrics ›› 2025, Vol. 39 ›› Issue (3): 217-222.doi: 10.3969/j.issn.1003-9198.2025.03.001
LI Xiang, LI Xuan, TIAN Yingxuan
Received:
2024-10-20
Online:
2025-03-20
Published:
2025-04-03
Contact:
TIAN Yingxuan, Email:tian_tyx@163.com
CLC Number:
LI Xiang, LI Xuan, TIAN Yingxuan. Epidemiological characteristics of chronic respiratory diseases in the elderly[J]. Practical Geriatrics, 2025, 39(3): 217-222.
[1] 梁瀚文, 易芳, 陈玥晗, 等. 中国慢性咳嗽流行病学调查的现状与展望[J]. 中华结核和呼吸杂志, 2022, 45(1): 100-106. [2] CHANGA B, GLOMBW B. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines[J]. Chest, 2006, 129(1 Suppl): 260S-283S. [3] MORICEA H, MILLQVIST E, BIEKSIENE K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children[J]. Eur Respir J, 2020, 55(1): 1901136. [4] SONGW J, CHANGY S, FARUQI S, et al. Defining chronic cough: a systematic review of the epidemiological literature[J]. Allergy Asthma Immunol Res, 2016, 8(2): 146. [5] SONGW J, CHANGY S, FARUQI S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis[J]. Eur Respir J, 2015, 45(5): 1479-1481. [6] 李婧辰, 张梅, 李镒冲, 等. 我国40岁及以上人群慢性呼吸系统疾病症状流行现况及影响因素研究[J]. 中华流行病学杂志, 2018, 39(6): 786-791. [7] LAI K, LONG L, YI F, et al. Age and sex distribution of Chinese chronic cough patients and their relationship with capsaicin cough sensitivity[J]. Allergy Asthma Immunol Res, 2019, 11(6): 871-884. [8] MORICEA H, JAKESA D, FARUQI S, et al. A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response[J]. Eur Respir J, 2014, 44(5): 1149-1155. [9] SPANEVELLO A, BEGHÉ B, VISCA D, et al. Chronic cough in adults[J]. Eur J Intern Med, 2020, 78: 8-16. [10] ANT J, KIMJ W, CHOIE Y, et al. Clinical characteristics of chronic cough in Korea[J]. Tuberc Respir Dis, 2020, 83(1): 31-41. [11] LAI K, LONG L. Current status and future directions of chronic cough in China[J]. Lung, 2020, 198(1): 23-29. [12] 李斌恺, 赖克方. 慢性咳嗽的流行病学[J]. 中华结核和呼吸杂志, 2010, 33(1): 62-66. [13] WILSON D, TAKAHASHI K, PAN G, et al. Respiratory symptoms among residents of a heavy-industry province in China: prevalence and risk factors[J]. Respir Med, 2008, 102(11): 1536-1544. [14] GUO X, FUJINO Y, CHAI J, et al. The prevalence of subjective symptoms after exposure to arsenic in drinking water in Inner Mongolia, China[J]. J Epidemiol, 2003, 13(4): 211-215. [15] 赖克方, 黄廉蓉, 陈玥晗, 等. 慢性咳嗽临床研究进展[J]. 中华结核和呼吸杂志, 2023, 46(10): 1022-1027. [16] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205. [17] ADELOYE D, SONG P, ZHU Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis[J]. Lancet Respir Med, 2022, 10(5): 447-458. [18] WANG C, XU J, YANG L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717. [19] LIU W, WANG W, LIU J, et al. Trend of mortality and years of life lost due to chronic obstructive pulmonary disease in China and its provinces, 2005-2020[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 2973-2981. [20] PAPAIOANNOU A I, HILLAS G, LOUKIDES S, et al. Mortality prevention as the centre of COPD management[J]. ERJ Open Res, 2024, 10(3): 00850-02023. [21] CHEN S, KUHN M, PRETTNER K, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study[J]. Lancet Glob Health, 2023, 11(8): e1183-e1193. [22] ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. [23] SAFIRI S, CARSON-CHAHHOUD K, NOORI M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019[J]. BMJ, 2022, 378: e069679. [24] HOLTJER J C S, BLOEMSMAL D, BEIJERS R J H C G, et al. Identifying risk factors for COPD and adult-onset asthma: an umbrella review[J]. Eur Respir Rev, 2023, 32(168): 230009. [25] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会,等. 中国慢性阻塞性肺疾病基层诊疗与管理指南(2024年)[J]. 中华全科医师杂志, 2024, 23(6): 578-602. [26] POLVERINO E, GOEMINNE P C, MCDONNELL M J, et al. European Respiratory Society guidelines for the management of adult bronchiectasis[J]. Eur Respir J, 2017, 50(3): 1700629. [27] 徐小勇, 施毅. 支气管扩张的诊断和治疗进展[J]. 中国呼吸与危重监护杂志, 2017,16(2): 186-190. [28] CHALMERS J D, POLVERINO E, CRICHTON M L, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)[J]. Lancet Respir Med, 2023, 11(7): 637-649. [29] NIGRO M, LASKA I F, TRAVERSI L, et al. Epidemiology of bronchiectasis[J]. Eur Respir Rev, 2024, 33(174): 240091. [30] FENG J, SUN L, SUN X, et al. Increasing prevalence and burden of bronchiectasis in urban Chinese adults, 2013-2017: a nationwide population-based cohort study[J]. Respir Res, 2022, 23(1): 111. [31] CHOI H, YANG B, KIM Y J, et al. Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities[J]. Sci Rep, 2021, 11(1): 7126. [32] MATEUS S P, RIBEIRO-ALVES M, SALLES R E B, et al. Mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up[J]. Medicine, 2022, 101(52): e32537. [33] ROBERTS J M, GOYAL V, KULARATNA S, et al. The economic burden of bronchiectasis: a systematic review[J]. Chest, 2023, 164(6): 1396-1421. [34] GUAN W J, GAOY H, XU G, et al. Aetiology of bronchiectasis in Guangzhou, Southern China[J]. Respirology, 2015, 20(5): 739-748. [35] GÓMEZ-OLIVAS J D, OSCULLO G, MARTÍNEZ-GARCÍA M Á. Etiology of bronchiectasis in the world: data from the published national and international registries[J]. J Clin Med, 2023, 12(18): 5782. [36] QI Q, XU J, WANG Y, et al. Decreased sphingosine due to down-regulation of acid ceramidase expression in airway of bronchiectasis patients: a potential contributor to Pseudomonas aeruginosa infection[J]. Infect Drug Resist, 2023, 16: 2573-2588. [37] WANG L L, LU H W, LI L L, et al. Pseudomonas aeruginosa isolation is an important predictor for recurrent hemoptysis after bronchial artery embolization in patients with idiopathic bronchiectasis: a multicenter cohort study[J]. Respir Res, 2023, 24(1): 84. [38] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. [39] 郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. [40] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clinicians, 2016, 66(2): 115-132. [41] YOUNG R P, HOPKINS R J, CHRISTMAS T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history[J]. Eur Respir J, 2009, 34(2): 380-386. [42] MCKAY J D, HUNG R J, HAN Y, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes[J]. Nat Genet, 2017, 49(7): 1126-1132. [43] SIGEL K, MAKINSON A, THALER J. Lung cancer in persons with HIV[J]. Curr Opin HIV AIDS, 2017, 12(1): 31-38. [44] XUE X J, GAO Q, QIAO J H, et al. Red and processed meat consumption and the risk of lung cancer: a dose-response meta-analysis of 33 published studies[J]. Int J Clin Exp Med, 2014, 7(6): 1542-1553. [45] WEI X, ZHU C, JI M, et al. Diet and risk of incident lung cancer: a large prospective cohort study in UK biobank[J]. Am J Clin Nutr, 2021, 114(6): 2043-2051. [46] 中华医学会呼吸病学分会, 中国医师协会呼吸医师分会. 间质性肺疾病多学科讨论规范中国专家共识[J]. 中华结核和呼吸杂志, 2023, 46(12): 1176-1188. [47] WIJSENBEEK M, COTTIN V. Spectrum of fibrotic lung diseases[J]. N Engl J Med, 2020, 383(10): 958-968. [48] FERNÁNDEZ FABRELLAS E, PERIS SÁNCHEZ R, SABATER ABAD C, et al. Prognosis and follow-up of idiopathic pulmonary fibrosis[J]. Med Sci, 2018, 6(2): 51. [49] LEE J H, PARK H J, KIM S, et al. Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study[J]. BMC Pulm Med, 2023, 23(1): 54. [50] 尹成胜, 张苑, 李惠萍. 特发性肺纤维化急性加重的研究进展[J]. 中华医学杂志, 2019, 99(8): 637-640. [51] PODOLANCZUK A J, THOMSON C C, REMY-JARDIN M, et al. Idiopathic pulmonary fibrosis: state of the art for 2023[J]. Eur Respir J, 2023, 61(4): 2200957. [52] GAGNEUX S. Ecology and evolution of Mycobacterium tuberculosis[J]. Nat Rev Microbiol, 2018, 16(4): 202-213. [53] World Health Organization. Global Tuberculosis Report 2023[R].Geneva:World Health Organization.2023. [54] World Health Organization. Global Tuberculosis Report 2024[R].Geneva:World Health Organization.2024. [55] 王歆尧, 姜美丽, 庞元捷, 等. 中国结核病疾病负担现状[J]. 中华流行病学杂志, 2024, 45(6): 857-864. [56] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会,等. 肺结核基层诊疗指南(2018年)[J]. 中华全科医师杂志, 2019, 18(8): 709-717. [57] 中华医学会结核病学分会. 老年肺结核诊断与治疗专家共识(2023版)[J]. 中华结核和呼吸杂志, 2023, 46(11): 1068-1084. [58] 张梦迪,王鑫,郑文静,等.老年结核病危险因素研究进展[J].中国防痨杂志,2024,46(10):1266-1272. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
|